Clinical Trial Update: Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of Avonex (interferon beta-1a) in chronic inflammatory demyelinating polyradiculoneuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 | Status: COMPLETED